Corrigendum to "LARS inhibition overcomes regorafenib resistance in hepatocellular carcinoma via ferroptosis and drug metabolism" [European Journal of Pharmaceutical Sciences 225 (2026)107614].
- DOI
- 10.1016/j.ejps.2026.107695
- Published
- 2026 Oct 25
- Container
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejps.2026.107695,
title = {Corrigendum to "LARS inhibition overcomes regorafenib resistance in hepatocellular carcinoma via ferroptosis and drug metabolism" [European Journal of Pharmaceutical Sciences 225 (2026)107614].},
author = {Tsai TY and Lin HH and Cheng YC and Yadav VK and Ko CC and Cherng YG and Lai SW},
year = {2026},
journal = {European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences},
doi = {10.1016/j.ejps.2026.107695},
url = {https://doi.org/10.1016/j.ejps.2026.107695}
}RIS
TY - JOUR TI - Corrigendum to "LARS inhibition overcomes regorafenib resistance in hepatocellular carcinoma via ferroptosis and drug metabolism" [European Journal of Pharmaceutical Sciences 225 (2026)107614]. AU - Tsai TY AU - Lin HH AU - Cheng YC AU - Yadav VK AU - Ko CC AU - Cherng YG AU - Lai SW PY - 2026 JO - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences DO - 10.1016/j.ejps.2026.107695 UR - https://doi.org/10.1016/j.ejps.2026.107695 ER -
APA
TY, T., HH, L., YC, C., VK, Y., CC, K., YG, C., & SW, L. (2026). Corrigendum to "LARS inhibition overcomes regorafenib resistance in hepatocellular carcinoma via ferroptosis and drug metabolism" [European Journal of Pharmaceutical Sciences 225 (2026)107614].. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2026.107695
Source records
- pubmed · retrieved 2026-11-10T15:00:15.511Z